Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine for juvenile myelomonocytic leukemia
jRCTs041210044Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of azacitidine in juvenile myelomonocytic leukemia (JMML), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Clinical response rate after 3 cycles. Started Jul 2021; status: active, not recruiting.
02
Drugs
azacitidine
03
Conditions
juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on jRCTs041210044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210044.